ProKidney (NASDAQ:PROK) Coverage Initiated at Guggenheim

Guggenheim started coverage on shares of ProKidney (NASDAQ:PROK – Free Report) in a research report released on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $6.00 target price on the stock. Several other research firms have also weighed in on PROK. Bank of America lowered their target price on ProKidney from $4.00 […]

Leave a Reply

Your email address will not be published.

Previous post Granite Point Mortgage Trust (NYSE:GPMT) versus Prologis (NYSE:PLD) Head to Head Analysis
Next post Campbell Soup (NASDAQ:CPB) PT Raised to $57.00 at JPMorgan Chase & Co.